- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active polyarticular juvenile idiopathic arthritis (JIA)
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Tocilizumab – March 2019
Tocilizumab: Injection 162 mg in 0.9 mL single use pre-filled pen; Actemra® (JIA)
Last updated
5 July 2019